A novel nanohybrid antimicrobial based on chitosan nanoparticles and antimicrobial peptide microcin J25 with low toxicity. (1st February 2021)

• Record Type: Journal Article
• Authors: Yu, Haitao; Ma, Zhengxin; Meng, Shanyu; Qiao, Shiyan; Zeng, Xiangfang; Tong, Zhaohui; Jeong, Kwangcheol Casey
• Is Part Of: Carbohydrate polymers. Volume 253(2021)
• Publication Date: 2021-02-01
• Subjects: Chitosan nanoparticles -- Antimicrobial peptide microcin J25 -- Antimicrobial activity -- Mutagenesis -- Toxicity -- Caenorhabditis elegans; Polysaccharides -- Periodicals; Polysaccharides -- Periodicals; Polysaccharides -- Périodiques; Electronic journals; 547.78
• DOI: 10.1016/j.carbpol.2020.117309
• Languages: English
• ISSNs: 0144-8617

Abstract

Graphical abstract: Highlights: We engineered chitosan nanoparticle-microcin J25 conjugates (CNMs). CNMs exerted strong antimicrobial activity. CNMs did not cause toxicity in cell lines. CNMs can serve as a promising antimicrobial to treat multi-drug resistant pathogens. Abstract: Bacterial resistance to antibiotics is a critical public health concern. Alternatives of antibiotics are needed urgently. Herein, we designed and engineered a new nano-antimicrobial, chitosan nanoparticles (CNs)-antimicrobial peptide microcin J25 (MccJ25) conjugates (CNMs). The engineered CNMs proved to be highly active against Gram-negative and Gram-positive bacteria, and the activity of CNMs and CNs was stable in various thermal and pH environments. Escherichia coli K88 strain treated with CNMs did not acquire resistance in serial passage assays over a period of 18 days. Risk assessment with cell lines showed that CNMs did not cause toxicity. Additionally, CNMs did not reduce the lifespan of C. elegans . In summary, this study demonstrated that CNMs can serve as an excellent novel antimicrobial agent against multi-drug resistance pathogens.